AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid for hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a treatment for relapsing forms of multiple sclerosis. It serves wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers. AbbVie Inc. has collaborations with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; International Myeloma Foundation; Calibr and Scripps Research; The Institute for Research in Immunology and Cancer Commercialization of Research; the Université de Montréal; Tolero Pharmaceuticals, Inc.; Galapagos; Mission Therapeutics Ltd; Bristol-Myers Squibb Company; Voluntis; Tizona Therapeutics, Inc.; and Voyager Therapeutics, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone847-932-7900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$32.75 billion
Profitability
Miscellaneous
Employees30,000
Next Earnings Date4/25/2019 (Estimated)
OptionableOptionable
AbbVie (NYSE:ABBV) Frequently Asked Questions
What is AbbVie's stock symbol?
AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."
How often does AbbVie pay dividends? What is the dividend yield for AbbVie?
AbbVie announced a quarterly dividend on Thursday, February 21st. Shareholders of record on Monday, April 15th will be given a dividend of $1.07 per share on Wednesday, May 15th. This represents a $4.28 annualized dividend and a dividend yield of 5.27%. The ex-dividend date of this dividend is Friday, April 12th. View AbbVie's Dividend History.
How will AbbVie's stock buyback program work?
AbbVie declared that its Board of Directors has initiated a stock repurchase plan on Thursday, December 13th 2018, which allows the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy up to 3.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's board of directors believes its shares are undervalued.
How were AbbVie's earnings last quarter?
AbbVie Inc (NYSE:ABBV) issued its quarterly earnings data on Friday, January, 25th. The company reported $1.90 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $1.92 by $0.02. The business earned $8.31 billion during the quarter, compared to analyst estimates of $8.37 billion. AbbVie had a negative return on equity of 439.07% and a net margin of 17.36%. The business's quarterly revenue was up 7.3% compared to the same quarter last year. During the same period last year, the firm posted $1.48 earnings per share. View AbbVie's Earnings History.
When is AbbVie's next earnings date?
What guidance has AbbVie issued on next quarter's earnings?
AbbVie issued an update on its FY19 earnings guidance on Friday, January, 25th. The company provided earnings per share guidance of $8.65-8.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.72. AbbVie also updated its FY 2019 guidance to $8.65-8.75 EPS.
What price target have analysts set for ABBV?
17 analysts have issued 12-month target prices for AbbVie's stock. Their predictions range from $65.61 to $135.00. On average, they expect AbbVie's share price to reach $94.0871 in the next year. This suggests a possible upside of 15.8% from the stock's current price. View Analyst Price Targets for AbbVie.
What is the consensus analysts' recommendation for AbbVie?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 4 sell ratings, 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie.
Has AbbVie been receiving favorable news coverage?
Media coverage about ABBV stock has trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AbbVie earned a media sentiment score of -1.1 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term.
Are investors shorting AbbVie?
AbbVie saw a decline in short interest in February. As of February 15th, there was short interest totalling 22,190,657 shares, a decline of 12.3% from the January 31st total of 25,312,582 shares. Based on an average daily volume of 5,973,348 shares, the short-interest ratio is currently 3.7 days. Currently, 1.5% of the shares of the company are short sold. View AbbVie's Current Options Chain.
Who are some of AbbVie's key competitors?
Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG) and Shire (SHPG).
What other stocks do shareholders of AbbVie own?
Who are AbbVie's key executives?
AbbVie's management team includes the folowing people:
- Mr. Richard A. Gonzalez, Chairman & CEO (Age 65)
- Dr. Michael E. Severino, Vice Chairman & Pres (Age 53)
- Mr. William J. Chase, Exec. VP of Fin. & Admin. (Age 51)
- Ms. Laura J. Schumacher, Vice Chairman of External Affairs & Chief Legal Officer (Age 56)
- Mr. Carlos Alban, Vice Chairman & Chief Commercial Officer (Age 56)
Who are AbbVie's major shareholders?
AbbVie's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.37%), Northern Trust Corp (1.40%), Geode Capital Management LLC (1.17%), Bank of New York Mellon Corp (1.06%), Oregon Public Employees Retirement Fund (1.01%) and Norges Bank (0.94%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.
Which institutional investors are selling AbbVie stock?
ABBV stock was sold by a variety of institutional investors in the last quarter, including Canada Pension Plan Investment Board, Dimensional Fund Advisors LP, First American Bank, Assenagon Asset Management S.A., First Trust Advisors LP, Brandywine Global Investment Management LLC, King Luther Capital Management Corp and HM Payson & Co.. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.
Which institutional investors are buying AbbVie stock?
ABBV stock was purchased by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Norges Bank, Vaughan Nelson Investment Management L.P., Bessemer Group Inc., Geode Capital Management LLC, Mn Services Vermogensbeheer B.V., Amundi Pioneer Asset Management Inc. and APG Asset Management N.V.. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp and Glenn F Tilton. View Insider Buying and Selling for AbbVie.
How do I buy shares of AbbVie?
Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AbbVie's stock price today?
One share of ABBV stock can currently be purchased for approximately $81.24.
How big of a company is AbbVie?
AbbVie has a market capitalization of $119.84 billion and generates $32.75 billion in revenue each year. The company earns $5.69 billion in net income (profit) each year or $7.91 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.
What is AbbVie's official website?
How can I contact AbbVie?
AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.
MarketBeat Community Rating for AbbVie (NYSE ABBV)
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe ABBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days.
